{
    "nct_id": "NCT05676931",
    "official_title": "A Phase II, Open-label, Platform Study, to Evaluate Immunotherapy-based Combinations in Participants With Advanced Non-Small Cell Lung Cancer",
    "inclusion_criteria": "* Histologically or cytologically documented Stage IV metastatic, NSCLC\n* Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1\n* At least one measurable target lesion per RECIST v1.1.\n* Adequate organ function\n* Participants must be willing to provide adequate tumor tissue\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Underlying medical conditions that, in the Investigator's or Sponsor's opinion, will make the administration of Investigational Product(s) (IPs) hazardous\n* Use of any live vaccines against infectious diseases within 28 days of first dose of IP(s).\n* Use of supra-physiologic doses of corticosteroids (> 10 mg/day of oral prednisone or equivalent) or immunosuppressive medications â‰¤ 14 days before the initiation of study treatment (absorbable topical corticosteroids are not excluded).\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n* Any active autoimmune disease or a documented history of autoimmune disease or syndrome that required systemic treatment in the past 2 years (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs), except for vitiligo or resolved childhood asthma/atopy\n\nNOTE: Other protocol defined Inclusion/Exclusion criteria may apply.",
    "miscellaneous_criteria": ""
}